Ernexa Therapeutics Inc. Lease, Cost
Ernexa Therapeutics Inc. (ERNA) reported Lease, Cost of $44.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-06
- Ernexa Therapeutics Inc. lease, cost for the quarter ending 2026-06-30 was $44.00K, a 18.52% decline year-over-year.
- Ernexa Therapeutics Inc. lease, cost for the quarter ending 2026-03-31 was $20.00K, a 61.54% decline year-over-year.
- Ernexa Therapeutics Inc. lease, cost for the quarter ending 2025-12-31 was $48.00K, a 7.69% decline year-over-year.
- Ernexa Therapeutics Inc. lease, cost for the quarter ending 2025-09-30 was $53.00K, a 95.97% decline year-over-year.
- Ernexa Therapeutics Inc. lease, cost for fiscal 2025 was $208.00K, a 96.04% decline from fiscal 2024.
- Ernexa Therapeutics Inc. lease, cost for fiscal 2024 was $5.26M, a 52.30% increase from fiscal 2023.
- Ernexa Therapeutics Inc. lease, cost for fiscal 2023 was $3.45M, a 422.09% increase from fiscal 2022.
- Ernexa Therapeutics Inc. lease, cost for fiscal 2022 was $661.00K, a 6.10% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $44.00K 10-Q · filed 2026-08-06 | $63.00K 10-Q · filed 2026-08-06 | $112.00K derived: sum of 3 quarters · filed 2026-08-06 | $165.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-11 | $68.00K derived: sum of 2 quarters · filed 2026-05-11 | $121.00K derived: sum of 3 quarters · filed 2026-05-11 | $175.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $101.00K derived: sum of 2 quarters · filed 2026-03-13 | $155.00K derived: sum of 3 quarters · filed 2026-08-06 | $208.00K 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $53.00K 10-Q · filed 2025-11-07 | $107.00K derived: sum of 2 quarters · filed 2026-08-06 | $160.00K 10-Q · filed 2025-11-07 | $211.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $54.00K 10-Q · filed 2026-08-06 | $106.00K 10-Q · filed 2026-08-06 | $158.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.47M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $52.00K 10-Q · filed 2026-05-11 | $104.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.42M derived: sum of 3 quarters · filed 2026-05-11 | $3.36M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.37M derived: sum of 2 quarters · filed 2026-03-13 | $3.31M derived: sum of 3 quarters · filed 2026-03-13 | $5.26M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $1.31M 10-Q · filed 2025-11-07 | $3.26M derived: sum of 2 quarters · filed 2025-11-07 | $5.20M 10-Q · filed 2025-11-07 | $6.94M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $1.94M 10-Q · filed 2025-08-13 | $3.89M 10-Q · filed 2025-08-13 | $5.63M derived: sum of 3 quarters · filed 2025-08-13 | $7.24M derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $1.95M 10-Q · filed 2025-05-07 | $3.68M derived: sum of 2 quarters · filed 2025-05-07 | $5.29M derived: sum of 3 quarters · filed 2025-05-07 | $5.34M derived: sum of 4 quarters · filed 2025-05-07 | |||
| 2023-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.35M derived: sum of 2 quarters · filed 2025-03-12 | $3.40M derived: sum of 3 quarters · filed 2025-03-12 | $3.45M 10-K · filed 2025-03-12 | |||
| 2023-09-30 | $1.61M 10-Q · filed 2024-11-12 | $1.66M derived: sum of 2 quarters · filed 2024-11-12 | $1.71M 10-Q · filed 2024-11-12 | $1.85M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $53.00K 10-Q · filed 2024-08-13 | $105.00K 10-Q · filed 2024-08-13 | $240.00K derived: sum of 3 quarters · filed 2024-08-13 | $422.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $52.00K 10-Q · filed 2024-05-14 | $187.00K derived: sum of 2 quarters · filed 2024-05-14 | $369.00K derived: sum of 3 quarters · filed 2024-05-14 | $545.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $317.00K derived: sum of 2 quarters · filed 2024-03-14 | $493.00K derived: sum of 3 quarters · filed 2024-03-14 | $661.00K 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $182.00K 10-Q · filed 2023-11-13 | $358.00K derived: sum of 2 quarters · filed 2023-11-13 | $526.00K 10-Q · filed 2023-11-13 | $694.00K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $176.00K 10-Q · filed 2023-08-11 | $344.00K 10-Q · filed 2023-08-11 | $512.00K derived: sum of 3 quarters · filed 2023-08-11 | $684.00K derived: sum of 4 quarters · filed 2023-08-11 | |||
| 2022-03-31 | $168.00K 10-Q · filed 2023-05-11 | $336.00K derived: sum of 2 quarters · filed 2023-05-11 | $508.00K derived: sum of 3 quarters · filed 2023-05-11 | $652.00K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $340.00K derived: sum of 2 quarters · filed 2023-03-20 | $484.00K derived: sum of 3 quarters · filed 2023-03-20 | $623.00K 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $172.00K 10-Q · filed 2022-11-14 | $172.08K 10-Q · filed 2021-11-12 | $316.00K derived: sum of 2 quarters · filed 2022-11-14 | $455.00K 10-Q · filed 2022-11-14 | $454.96K 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $144.00K 10-Q · filed 2022-08-11 | $144.06K 10-Q · filed 2021-08-13 | $283.00K 10-Q · filed 2022-08-11 | $282.88K 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | $139.00K 10-Q · filed 2022-07-01 | $138.82K 10-Q · filed 2021-05-17 | |||||
| 2020-12-31 | $535.00K 10-K/A · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |